Intercept Pharmaceuticals Stock News

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

Binary events on the way could send these drugmaker stocks through the roof, or push them down in the dirt.

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has a beta value of 1.42 and has seen 1.31 million shares traded in the last trading session. The company, currently valued at $431.92M, closed the last trade at $16.67 per share which meant it lost -$0.47 on the day or -2.74% during that session. The ICPT stock price is -133.59% Intercept Pharmaceuticals Inc. (ICPT): What Makes The Stock Good? Read More »

Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year Study remains ongoing; top-line data anticipated in Q1 2022 versus near the end of the year

Shorted stocks continue to be of interest to retail traders looking for the next big day trade and we're diving into some top candidates! The post The 10 Most Shorted Stocks Right Now for Friday, Dec.

During the last session, Intercept Pharmaceuticals Inc. (NASDAQ:ICPT)s traded shares were 1.31 million, with the beta value of the company hitting 1.42. At the end of the trading day, the stocks price was $15.09, reflecting an intraday gain of 5.67% or $0.81. The 52-week high for the ICPT share is $38.94, that puts it down What To Expect Going Ahead For Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) Given Its 5.67 Percent Gain On Wednesday? Read More »

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 6.45% this past week. This is why it happened.

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.

Investors need to pay close attention to Intercept (ICPT) stock based on the movements in the options market lately.

Intercept (ICPT) withdraws its application seeking approval for OCA for the treatment of liver fibrosis due to nonalcoholic steatohepatitis in the EU. Resultantly, the stock declines.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) has been assigned a consensus recommendation of Hold from the eighteen analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating on the company. The average 1-year []

The stock price of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) fell by 14.87% today. This is why it happened.

Intercept Pharmaceuticals Inc (NASDAQ: ICPT ) has withdrawn its European marketing application seeking approval for obeticholic acid (OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH). The initial application was filed in December 2019 was supported by the interim analysis results from the Phase 3 REGENERATE study, which remains ongoing. Intercept says it expects Full story available on Benzinga.com

The small cap biotech space offers a powerful dimension for active investors because it is comprised of stocks with little or no consistent correlation with the broad market, creating diversification without sacrificing explosive upside potential. But the group is best handled in baskets. In other words, investors may stand to benefit from cultivating exposure to [] The post Top Ideas in the Small Cap Biotech Space (INMB, OTLC, DVAX, SAVA, ICPT, IMGN) appeared first on Wall Street PR .